Gastroesophageal Junction Adenocarcinoma
📧 Sign up to get email alerts when something new happens for Gastroesophageal Junction Adenocarcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-12-17Clinical Trial Update: Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC) [Phase 2]
Phase 2 trial investigating a quadruple combination of Iparomlimab, Tuvonralimab, Apatinib, and Irinotecan hydrochloride for advanced Alpha-…
-
CLINICAL_TRIALS trial_result · 2025-12-16Clinical Trial Update: GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer [Phase 2]
Phase 2 clinical trial update shows GEN-001 in combination with Avelumab for PD-L1 positive gastric cancer and gastroesophageal junction ade…
-
CLINICAL_TRIALS research · 2025-12-16Clinical Trial Update: Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma [Phase 2]
Phase 2 clinical trial evaluating propranolol in combination with pembrolizumab and standard chemotherapy for unresectable or metastatic eso…
-
CLINICAL_TRIALS trial_result · 2025-12-15Clinical Trial Update: A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors [Phase 1]
A Phase 1 study of SGN-B6A in Chinese participants with advanced solid tumors has completed, reporting safety and preliminary activity acros…
-
CLINICAL_TRIALS trial_result · 2025-12-15Clinical Trial Update: Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. [Phase 3]
A Phase 3 trial evaluating bemarituzumab added to chemotherapy and nivolumab versus chemotherapy and nivolumab in FGFR2b-overexpressing untr…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-12-15Clinical Trial Update: A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) [Phase 1, Phase 2]
A Roche-sponsored Phase 1/2 clinical trial evaluating multiple immunotherapy-based treatment combinations in patients with locally advanced …
-
CLINICAL_TRIALS research · 2025-12-10Clinical Trial Update: Zanidatamab Combined With Chemotherapy as Neoadjuvant Therapy for HER2-high Expression G/GEJC [Phase 2]
A Phase 2 neoadjuvant trial is evaluating Zanidatamab in combination with chemotherapy for HER2-high gastric/gastroesophageal junction adeno…
-
CLINICAL_TRIALS trial_result · 2025-12-04Clinical Trial Update: Biomarker Analysis of Tislelizumab Combined With Chemotherapy for Perioperative Treatment of G/GEJ Adenocarcinoma
Completed clinical trial update reporting biomarker analysis for the tislelizumab-chemotherapy combination as perioperative treatment for ga…
-
CLINICAL_TRIALS research · 2025-12-02Clinical Trial Update: Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment: An Adaptive Trial (MRD-ATLAS) [Phase 2]
This Phase 2 study (MRD-ATLAS) is evaluating whether circulating tumor DNA–based minimal residual disease guidance can inform adjuvant thera…
-
CLINICAL_TRIALS research · 2025-11-28Clinical Trial Update: Hypofractionated Radiotherapy Combined With Immunochemotherapy for Conversion Treatment of Gastroesophageal Junction Adenocarcinoma [Phase 1, Phase 2]
An ongoing phase 1/2 trial evaluating hypofractionated radiotherapy combined with immunochemotherapy as conversion therapy for gastroesophag…
-
CLINICAL_TRIALS trial_result · 2025-11-28Clinical Trial Update: Study of ACC-1898 in Adult Participants With Advanced Solid Tumors [Phase 1]
Phase 1 study update for ACC-1898 in adults with advanced solid tumors; the trial is not yet recruiting.
-
CLINICAL_TRIALS research · 2025-11-24Clinical Trial Update: Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET) [Phase 2]
A Phase II basket trial is evaluating Zanidatamab in combination with Tislelizumab for HER2-positive gastrointestinal tumors, including rect…
-
CLINICAL_TRIALS trial_result · 2025-11-19Clinical Trial Update: A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma [Phase 3]
A Phase 3 trial evaluating AK104 as first-line therapy for locally advanced unresectable or metastatic gastric adenocarcinoma and gastroesop…
-
CLINICAL_TRIALS research · 2025-11-19Clinical Trial Update: A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma [Phase 1, Phase 2]
This clinical trial update reports ongoing Phase 1/2 studies evaluating AK109 and AK104 in advanced gastric cancer and gastroesophageal junc…
-
CLINICAL_TRIALS research · 2025-11-18Clinical Trial Update: A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers [Phase 2]
Phase II clinical study evaluating SSGJ-706 in combination therapy for advanced gastrointestinal cancers is not yet recruiting. The study in…
-
CLINICAL_TRIALS research · 2025-11-18Clinical Trial Update: Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma [Phase 2]
Phase II open-label study evaluating HLX43, an anti-PD-L1 ADC, for advanced gastric or gastroesophageal junction adenocarcinoma; recruitment…
-
CLINICAL_TRIALS trial_result · 2025-11-17Clinical Trial Update: Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1 [Phase 1, Phase 2]
A phase 1/2 trial evaluating afuresertib in combination with sintilimab and chemotherapy in selected solid tumors resistant to prior PD-1/PD…
-
CLINICAL_TRIALS research · 2025-11-17Clinical Trial Update: A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-positive Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction Adenocarcinoma [Phase 3]
This is a Phase 3 clinical trial comparing BL-M07D1 to investigator's choice chemotherapy in HER2-positive locally advanced or metastatic ga…
-
CLINICAL_TRIALS research · 2025-11-14Clinical Trial Update: Folfox+Irinotecan+Chemort In Esophageal Cancer [Phase 2]
Phase 2 clinical trial evaluating a FOLFOX plus Irinotecan regimen with chemotherapy for gastroesophageal junction adenocarcinoma and esopha…
-
CLINICAL_TRIALS research · 2025-10-16Clinical Trial Update: Tadalafil Effect + Chemotherapy in Resectable Gastric/GEJ Cancer [Phase 2]
Phase 2 trial evaluating tadalafil in combination with chemotherapy for resectable gastric or gastroesophageal junction adenocarcinoma; curr…
-
CLINICAL_TRIALS research · 2025-10-01Clinical Trial Update: To Evaluate the Efficacy of CT041 in Sequential Treatment After First-line Treatment of Advanced Gastric/Esophagogastric Junction Adenocarcinoma
A clinical trial evaluating the efficacy of CT041 in sequential treatment after first-line therapy for advanced gastric cancer and gastroeso…
-
CLINICAL_TRIALS research · 2025-10-01Clinical Trial Update: Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies [Phase 1]
A Phase 1 clinical trial update evaluating the safety of a quadruple chemotherapy combination (irinotecan with 5-FU/leucovorin, oxaliplatin,…
-
CLINICAL_TRIALS trial_result · 2025-09-12Clinical Trial Update: Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors [Phase 1]
Phase 1a/1b study of TPST-1495 as monotherapy and in combination with pembrolizumab has completed status, spanning multiple solid tumors inc…
-
CLINICAL_TRIALS research · 2025-09-10Clinical Trial Update: Early Access Program for Zolbetuximab
It provides an update on the Early Access Program for zolbetuximab in patients with locally advanced unresectable or metastatic gastric or g…
-
CLINICAL_TRIALS research · 2025-09-10Clinical Trial Update: Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma [Phase 2]
A Phase 2 clinical trial is assessing SHR2554 in combination with other antitumor therapies for advanced/metastatic gastric cancer and gastr…